Anti-MDA5 Dermatomyositis — RACP Adult Medicine MCQ
Instant feedback + full explanation. One question, done properly.
Educational content. Not a substitute for clinical judgement or local policy.
Reveal the answer and explanation
Correct answer: B — Rapidly progressive interstitial lung disease
Anti-MDA5 antibody-positive dermatomyositis is associated with rapidly progressive interstitial lung disease (RP-ILD), which carries a mortality rate of 50–80% without aggressive immunosuppression. The combination of V-sign rash, mechanic's hands, mild CK elevation (amyopathic or hypomyopathic dermatomyositis), and positive anti-MDA5 should prompt urgent ILD screening and aggressive treatment (typically triple immunosuppression with corticosteroids, calcineurin inhibitor, and cyclophosphamide).
Reference: eTG – 2025 – Rheumatology; ACR/EULAR – 2017 – Myositis Classification